NCT04803864

Study of Roxadustat in the Treatment of Acute Myocardial Infarction

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Roxadustat in Patients With Acute ST Elevation Myocardial Infarction

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 158 (estimated)
• Sponsor: Ruijin Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Depite successful primary percutaneous coronary intervention (PCI) and standardized medical treatment, prognosis of acute ST-elevation myocardial infarction patents are still a poor, with high morality and various complications such as heart failure. Roxadustat is a new drug targeting hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibition and has shown promising effect in reducing infarct size in pre-clinical studies. This study aims to evaluate the efficacy and safety of early and short-term administration of roxadustat in the treatment of acute ST-elevation myocardial infarction.

Detailed description

This study is an open-label, paralleled, randomized controlled trial. It aims to evaluate the efficacy and safety of early and short-term administration of roxadustat in the treatment of acute ST-elevation myocardial infarction.

Conditions

• ST Elevation Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Roxadustat	Orally 100mg, 3 times per week for 2 weeks First dose administered immediately after successful PCI.

Timeline

• Start date: 2021-06-10
• Primary completion: 2022-09-30
• Completion: 2023-08-31
• First posted: 2021-03-18
• Last updated: 2021-09-01

Locations

1 site across 1 country: China